Polyethylene glycol-b-poly(lactic acid) polymersomes as vehicles for enzyme replacement therapy

Jessica M. Kelly; Amanda L. Gross; Douglas R. Martin; Mark E. Byrne

doi:10.2217/nnm-2017-0221

Polyethylene glycol-b-poly(lactic acid) polymersomes as vehicles for enzyme replacement therapy

Jessica M. Kelly
, Amanda L. Gross
, Douglas R. Martin
, Mark E. Byrne

Research output: Contribution to journal › Article › peer-review

42 Scopus citations

Abstract

Aim: Polymersomes are created to deliver an enzyme-based therapy to the brain in lysosomal storage disease patients. Materials & methods: Polymersomes are formed via the injection method using poly(ethylene glycol)-b-poly(lactic acid) (PEGPLA) and bound to apolipoprotein E, to create a brain-targeted delivery vehicle. Results: Polymersomes have a smallest average diameter of 145 ± 21 nm and encapsulate β-galactosidase at 72.0 ± 12.2% efficiency. PEGPLA polymersomes demonstrate limited release at physiologic pH (7.4), with a burst release at the acidic pH (4.8) of the lysosome. PEGPLA polymersomes facilitate delivery of active β-galactosidase to an in vitro model of GM1 gangliosidosis. Conclusion: The foundation has been laid for testing of PEGPLA polymersomes to deliver enzymatic treatments to the brain in lysosomal storage disorders for the first time.

Original language	English (US)
Pages (from-to)	2591-2606
Number of pages	16
Journal	Nanomedicine
Volume	12
Issue number	23
DOIs	https://doi.org/10.2217/nnm-2017-0221
State	Published - Dec 2017
Externally published	Yes

All Science Journal Classification (ASJC) codes

Bioengineering
Medicine (miscellaneous)
Biomedical Engineering
General Materials Science
Development

Access to Document

10.2217/nnm-2017-0221

Cite this

@article{1a9ff76659884d4288cc43fc91e8a854,

title = "Polyethylene glycol-b-poly(lactic acid) polymersomes as vehicles for enzyme replacement therapy",

abstract = "Aim: Polymersomes are created to deliver an enzyme-based therapy to the brain in lysosomal storage disease patients. Materials \& methods: Polymersomes are formed via the injection method using poly(ethylene glycol)-b-poly(lactic acid) (PEGPLA) and bound to apolipoprotein E, to create a brain-targeted delivery vehicle. Results: Polymersomes have a smallest average diameter of 145 ± 21 nm and encapsulate β-galactosidase at 72.0 ± 12.2\% efficiency. PEGPLA polymersomes demonstrate limited release at physiologic pH (7.4), with a burst release at the acidic pH (4.8) of the lysosome. PEGPLA polymersomes facilitate delivery of active β-galactosidase to an in vitro model of GM1 gangliosidosis. Conclusion: The foundation has been laid for testing of PEGPLA polymersomes to deliver enzymatic treatments to the brain in lysosomal storage disorders for the first time.",

author = "Kelly, \{Jessica M.\} and Gross, \{Amanda L.\} and Martin, \{Douglas R.\} and Byrne, \{Mark E.\}",

note = "Publisher Copyright: {\textcopyright} 2017 2017 Future Medicine Ltd.",

year = "2017",

month = dec,

doi = "10.2217/nnm-2017-0221",

language = "English (US)",

volume = "12",

pages = "2591--2606",

journal = "Nanomedicine",

issn = "1743-5889",

publisher = "Taylor and Francis Ltd.",

number = "23",

}

TY - JOUR

T1 - Polyethylene glycol-b-poly(lactic acid) polymersomes as vehicles for enzyme replacement therapy

AU - Kelly, Jessica M.

AU - Gross, Amanda L.

AU - Martin, Douglas R.

AU - Byrne, Mark E.

PY - 2017/12

Y1 - 2017/12

N2 - Aim: Polymersomes are created to deliver an enzyme-based therapy to the brain in lysosomal storage disease patients. Materials & methods: Polymersomes are formed via the injection method using poly(ethylene glycol)-b-poly(lactic acid) (PEGPLA) and bound to apolipoprotein E, to create a brain-targeted delivery vehicle. Results: Polymersomes have a smallest average diameter of 145 ± 21 nm and encapsulate β-galactosidase at 72.0 ± 12.2% efficiency. PEGPLA polymersomes demonstrate limited release at physiologic pH (7.4), with a burst release at the acidic pH (4.8) of the lysosome. PEGPLA polymersomes facilitate delivery of active β-galactosidase to an in vitro model of GM1 gangliosidosis. Conclusion: The foundation has been laid for testing of PEGPLA polymersomes to deliver enzymatic treatments to the brain in lysosomal storage disorders for the first time.

AB - Aim: Polymersomes are created to deliver an enzyme-based therapy to the brain in lysosomal storage disease patients. Materials & methods: Polymersomes are formed via the injection method using poly(ethylene glycol)-b-poly(lactic acid) (PEGPLA) and bound to apolipoprotein E, to create a brain-targeted delivery vehicle. Results: Polymersomes have a smallest average diameter of 145 ± 21 nm and encapsulate β-galactosidase at 72.0 ± 12.2% efficiency. PEGPLA polymersomes demonstrate limited release at physiologic pH (7.4), with a burst release at the acidic pH (4.8) of the lysosome. PEGPLA polymersomes facilitate delivery of active β-galactosidase to an in vitro model of GM1 gangliosidosis. Conclusion: The foundation has been laid for testing of PEGPLA polymersomes to deliver enzymatic treatments to the brain in lysosomal storage disorders for the first time.

UR - https://www.scopus.com/pages/publications/85034442467

UR - https://www.scopus.com/pages/publications/85034442467#tab=citedBy

U2 - 10.2217/nnm-2017-0221

DO - 10.2217/nnm-2017-0221

M3 - Article

C2 - 29111890

AN - SCOPUS:85034442467

SN - 1743-5889

VL - 12

SP - 2591

EP - 2606

JO - Nanomedicine

JF - Nanomedicine

IS - 23

ER -

Polyethylene glycol-b-poly(lactic acid) polymersomes as vehicles for enzyme replacement therapy

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this